NVO starts_phase-3_for_Rybelsus_(oral_semaglutide)_in_AD: https://www.globenewswire.com/news-release/2020/12/16/2146164/0/en/Novo-Nordisk-to-enter-phase-3-development-in-Alzheimer-s-disease-with-oral-semaglutide.html